Transrectal ultrasound for monitoring murine orthotopic prostate tumor

BACKGROUND The mouse orthotopic prostate tumor model has been recognized as an ideal preclinical animal model simulating the anatomical and biological milieu of the prostate. In comparison with the subcutaneous tumor model, the only disadvantage of this model is the difficulty of chronological tumor...

Full description

Saved in:
Bibliographic Details
Published in:The Prostate 2001-05, Vol.47 (2), p.118-124
Main Authors: Kusaka, Nobuyuki, Nasu, Yasutomo, Arata, Ryoji, Saika, Takashi, Tsushima, Tomoyasu, Kraaij, Robert, Bangma, Chris H., Kumon, Hiromi
Format: Article
Language:English
Subjects:
animal model
Animals
Antineoplastic Agents - pharmacology
Cell Division - drug effects
Cisplatin - pharmacology
Disease Models, Animal
Male
Mice
Mice, Inbred C57BL
Monitoring, Physiologic - methods
orthotopic implantation
Prostate - diagnostic imaging
Prostate - pathology
prostate cancer
Prostatic Neoplasms - diagnostic imaging
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - pathology
Tumor Cells, Cultured
Ultrasonography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND The mouse orthotopic prostate tumor model has been recognized as an ideal preclinical animal model simulating the anatomical and biological milieu of the prostate. In comparison with the subcutaneous tumor model, the only disadvantage of this model is the difficulty of chronological tumor growth monitoring. We have applied recent endoluminal ultrasound technology, transrectal ultrasonography (TRUS), to the monitoring of mouse orthotopic prostate tumors. METHODS A 6 Fr. 20 MHz catheter‐based radial scan probe was used and TRUS was performed without any prior preparation including anesthesia. Orthotopic tumors were initiated by inoculation of 5000 RM‐9 cells into the dorsal prostate of 12‐week‐old C57BL/6 male mice. The tumor growth was monitored by TRUS from day 3 to day 21. In addition, TRUS was performed to detect tumor growth suppression after intraperitoneal administration of cis‐diamminedichloroplatinum (CDDP). RESULTS By ultrasound, tumors became detectable 7 days after tumor cell inoculation. TRUS images were clear and parallel to actual tumor growth. The tumor volume (X) calculated by TRUS correlated significantly with the actual tumor weight (Y) measured at autopsy; Y = 101.653 + 1.174X (R = 0.930, P 
ISSN:0270-4137
1097-0045
DOI:10.1002/pros.1054